ASC Daily Briefing — July 18, 2026
🆕 New Today
No new items today. See the Standing Compliance Reference for items currently in effect.
Today’s searches surfaced only items already captured on the standing Page or in recent briefings: the CY 2027 OPPS/ASC Proposed Rule (CMS-1850-P, docket CMS-2026-2344, comment deadline August 31, 2026 — proposed 2.4% ASC payment update, ~618 procedures proposed for addition to the ASC Covered Procedures List, IPO-list Year 2 removals, ASCQR measure changes, botulinum-toxin prior-authorization expansion, the AO/EMTALA deeming proposal, and the hospital price-transparency RFI), the CY 2026 OPPS/ASC Final Rule (CMS-1834-FC) in effect (2.6% update, expanded ASC CPL, IPO-list phase-out), the Conditions for Coverage at 42 CFR Part 416, the HHS Section 504 accessible medical diagnostic equipment (MDE) baseline (effective July 8, 2026) and extended Section 504 digital-accessibility deadlines (May 11, 2027 / May 10, 2028), price-transparency enforcement, the 10-state ASC prior-authorization demonstration (41 codes), AAAHC v44/v45, TJC 2026 standards, the five CMS-approved ASC accreditors (AAAHC, ACHC, DNV, TJC, QUAD A), the CMS AO-oversight final rule (Strengthening Oversight of Accrediting Organizations, 42 CFR Part 488), the HHS-OIG 2026 Work Plan, and the Ohio CRNA physician-supervision opt-out (27th state, effective July 10, 2026 — now on the standing Page).
No new enforcement actions, accreditation announcements, or additional Federal Register ASC notices appeared today. ASC Focus surfaced nothing new dated within the last ~30 days.
Reminder: the CY 2027 Proposed Rule comment deadline (August 31, 2026) remains the next actionable date — 44 days out. Calendar it now if commenting on the proposed 2.4% payment update, the ~618 proposed ASC CPL additions, IPO-list Year 2 removals, ASCQR measure changes, or the botulinum-toxin prior-authorization expansion.